Sandu Pharmaceuticals Reports Decline in Sales, Faces Financial Challenges in March 2025

Sandu Pharmaceuticals, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results indicate a notable shift in the company's performance metrics, leading to an adjustment in its evaluation.
The net sales for the quarter stood at Rs 14.07 crore, reflecting a decline compared to the average net sales of Rs 17.18 crore over the previous four quarters. This marks the lowest sales figure recorded in the last five quarters, suggesting a challenging environment for the company. The near-term sales trend appears to be unfavorable, indicating potential difficulties in maintaining revenue levels.

In light of these developments, Sandu Pharmaceuticals has experienced a revision in its score, which has moved from 5 to -3 over the past three months. This change underscores the current challenges faced by the company as it navigates through a period of financial strain.

For those interested in further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.